Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A, Jäschke K, Jousseaume E, Templin C, Jeratsch U, Kosmides D, Steffen I, Gökbuget N, Peters C. V Stackelberg A, et al. Leukemia. 2023 Dec;37(12):2346-2355. doi: 10.1038/s41375-023-02042-4. Epub 2023 Oct 25. Leukemia. 2023. PMID: 37880478 Free PMC article.

The OS(ITT, adjusted), EFS(FAS,naive) and RFS(FAS,naive) survival probability at 2 years was 59.49% for tisagenlecleucel vs. 36.16% for SOC population, 42.31% vs. 30.23% and 59.60% vs. 54.57%, respectively. Odds ratio for ORR(ITT,adjusted) was 1.99 (1.33-2.97, p < 0.001

…
The OS(ITT, adjusted), EFS(FAS,naive) and RFS(FAS,naive) survival probability at 2 years was 59.49% for tisagenlecleucel vs. 36.16% for SOC …
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV. Socinski MA, et al. J Clin Oncol. 2008 Feb 1;26(4):650-6. doi: 10.1200/JCO.2007.13.9303. J Clin Oncol. 2008. PMID: 18235126 Free PMC article. Clinical Trial.
RESULTS: Of the 63 patients treated with sunitinib, seven patients had confirmed partial responses, yielding an ORR of 11.1% (95% CI, 4.6% to 21.6%). An additional 18 patients (28.6%) experienced stable disease of at least 8 weeks in duration. ...CONCLUSION: Sunitinib has …
RESULTS: Of the 63 patients treated with sunitinib, seven patients had confirmed partial responses, yielding an ORR of 11.1% (95% CI, …